Open AccessDisparities in Access to Sorafenib in Communities with Low Socioeconomic Status
Author(s) -
Umut Sarpel,
Marina Heskel,
John Spivack,
Yael Feferman,
Celina Ang,
Francesca Gany
Publication year - 2018
Publication title -
journal of health care for the poor and underserved
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.511
H-Index - 59
eISSN - 1548-6869
pISSN - 1049-2089
DOI - 10.1353/hpu.2018.0083
Subject(s) - socioeconomic status , residence , medicine , sorafenib , medical prescription , demography , ethnic group , odds , odds ratio , hepatocellular carcinoma , environmental health , gerontology , logistic regression , population , political science , sociology , law , pharmacology
In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed with later-stage cancers. Sorafenib is the primary treatment for advanced HCC, however its substantial cost raises concern for access to treatment.